Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$2.44 USD
-0.12 (-4.69%)
Updated Nov 13, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
02/25/2025
Time: -- |
12/2024 | $-0.14 | -1.45% |
Earnings Summary
For their last quarter, Aclaris Therapeutics (ACRS) reported earnings of -$0.11 per share, missing the Zacks Consensus Estimate of -$0.08 per share. This reflects a negative earnings surprise of 37.50%. Look out for ACRS's next earnings release expected on February 25, 2025. For the next earning release, we expect the company to report earnings of -$0.14 per share, reflecting a year-over-year increase of 53.33%.
Earnings History
Price & Consensus
Zacks News for ACRS
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
ACRS FAQs
Based on past history, Zacks believes Aclaris Therapeutics, Inc. (ACRS) will report their next quarter earnings on February 25, 2025. For the next earning release, we expect the company to report earnings of -0.14 per share, reflecting a year-over-year increase of 53.33.
Based on past history, Zacks believes Aclaris Therapeutics, Inc. (ACRS) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on February 25, 2025.
The Zacks Consensus Estimate for Aclaris Therapeutics, Inc. (ACRS) for the quarter ending in December 2024 is $-0.14 a share. We expect Aclaris Therapeutics, Inc. to miss by -1.45%.
In the earnings report for the quarter ending in June 2024, Aclaris Therapeutics, Inc. (ACRS) announced earnings of $-0.15 per share versus the Zacks Consensus Estimate of $-0.19 per share, representing a surprise of -21.05%.